Synaffix BV, acquired by Lonza in 2023, is a biotech company that has established a proprietary, clinical-stage technology platform that enables best-in-class antibody-drug conjugates (ADCs) in terms of safety and efficacy. The technology out-licensing business has already translated into 5 ADCs entering the clinic, more than >30 distinct ADC programs being developed across our >17 partners and over $10.0 billion in total potential value from our out-licensing deals. Our partners include top-tier biotech and pharma companies such as Mersana Therapeutics, Shanghai Miracogen (acquired by Lepu Biopharma), Innovent Biologics, Kyowa Kirin, Genmab, Macrogenics, Amgen, Hummingbird Biosciences, Chong Kun Dang Pharma, ABL Bio, SOTIO Biotech, Kivu Bioscience, BigHat Biosciences, Illumina, Elevation Oncology, Mitsubishi Tanabe Pharma Corporation (MTPC) and Boehringer Ingelheim. Synaffix offers a consolidated ADC platform technology that enables any company with an antibody to develop a proprietary, best-in-class ADC. Rather than developing a pipeline of our own drugs, the business model of Synaffix is technology out-licensing where we regularly engage in discovery research collaborations with companies that are interested in developing highly competitive ADC Products using our proprietary technology.